249 related articles for article (PubMed ID: 21322783)
1. Current treatment options for primary immune thrombocytopenia.
Salama A
Expert Rev Hematol; 2011 Feb; 4(1):107-18. PubMed ID: 21322783
[TBL] [Abstract][Full Text] [Related]
2. [New treatment options for primary immune thrombocytopenia].
Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
[TBL] [Abstract][Full Text] [Related]
3. Current status of thrombopoietic agents.
Rhodes E; Stasi R
Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
Lee D; Thornton P; Hirst A; Kutikova L; Deuson R; Brereton N
Appl Health Econ Health Policy; 2013 Oct; 11(5):457-69. PubMed ID: 23857462
[TBL] [Abstract][Full Text] [Related]
5. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
6. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T
Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804
[No Abstract] [Full Text] [Related]
7. New therapeutic options for immune thrombocytopenia.
Schipperus M; Fijnheer R
Neth J Med; 2011; 69(11):480-5. PubMed ID: 22173361
[TBL] [Abstract][Full Text] [Related]
8. Immune thrombocytopenia -- what are the new treatment options?
Hallam S; Provan D; Newland AC
Expert Opin Biol Ther; 2013 Aug; 13(8):1173-85. PubMed ID: 23682685
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
[No Abstract] [Full Text] [Related]
11. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Imbach P; Crowther M
N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
[No Abstract] [Full Text] [Related]
12. Thrombopoietin-receptor agonists for immune thrombocytopenia.
Jansen AJ; Swart RM; te Boekhorst PA
N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
[No Abstract] [Full Text] [Related]
13. New thrombopoietin receptor agonists for platelet disorders.
Homeida S; Ebdon C; Batty P; Jackson B; Kolade S; Bateman C; Peng YY; Stasi R
Drugs Today (Barc); 2012 Apr; 48(4):293-301. PubMed ID: 22536571
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin receptor agonists in the treatment of thrombocytopenia.
Newland A
Curr Opin Hematol; 2009 Sep; 16(5):357-64. PubMed ID: 19553811
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin: too much or too little.
Newland A
Hematology; 2012 Apr; 17 Suppl 1():S166-8. PubMed ID: 22507811
[TBL] [Abstract][Full Text] [Related]
16. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
[TBL] [Abstract][Full Text] [Related]
17. Moving towards a new era in the management of chronic immune thrombocytopenia.
Wadenvik H; Olsson B
Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
[TBL] [Abstract][Full Text] [Related]
18. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
19. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
[TBL] [Abstract][Full Text] [Related]
20. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
